Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs
17 december, 2025
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces several new leadership appointments across clinical development, translational medicine, toxicology, and CMC. These additions reinforce the company’s operational platform and position Saniona to efficiently advance its differentiated CNS pipeline toward upcoming clinical and regulatory value inflection points.
“Saniona now has the leadership infrastructure to unlock the significant value potential of our CNS pipeline. These appointments reflect our commitment to disciplined execution and to delivering meaningful clinical results that can create long-term shareholder value,” said Thomas Feldthus, Saniona’s Chief Executive Officer.
The appointments expand Saniona’s core capabilities to progress its CNS assets, including SAN2219 for refractory focal onset seizures, SAN2465 for major depressive disorder, and SAN2668, recently selected as a first-inclass clinical candidate for pediatric epilepsy. All three programs are funded through Phase 1 readouts and are supported by newly filed compound patents providing protection into the 2040s, and each program has first-in-class potential in its respective indication. Phase 2 studies are planned to start in 2028. The expanded leadership team is expected to accelerate development timelines, enhance operational efficiency, and support forthcoming regulatory interactions.
Leadership Commentary
“These appointments significantly enhance our ability to design and execute clinical studies with a rigorous, data-driven approach, increasing the probability of success across our CNS programs,” said Pierandrea Muglia, Chief Medical Officer.
“With expanded capabilities in toxicology and CMC, we can advance our programs efficiently and maintain a proactive regulatory strategy as we enter our next phase of growth,” said Janus Larsen, Chief Operating Officer.
Strategic Leadership Appointments
- Stina Westergaard Frederiksen – Head of Clinical Operations
Over 20 years of clinical development experience across biotech and large pharma, leading programs from design through late-stage execution and building high-performing operational teams. - Martin Damm Olling – Head of Clinical Development
Brings 24 years of R&D expertise from small and large pharma, including two decades in CNS drug development, with successful FDA and EMA approvals and deep experience in clinical strategy and regulatory pathways. - Isabella Premoli – Director of Translational Medicine
Neuroscientist with broad biomarker experience (EEG, TMS, electrophysiology, imaging) and leadership of translational strategies in early-phase research from both biotech and academia. - Alex Rodriguez – Head of Toxicology
More than 20 years of nonclinical and regulatory toxicology experience at large pharma and small pharma companies, including IND and CTA submissions and early-stage development of CNS and small-molecule programs. - Søren Ebdrup – Head of CMC
25 years of small-molecule development experience at mid- and large pharma, overseeing CMC activities across preclinical and clinical phases.
For more information, please contact
Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com
About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for paediatric epilepsy syndromes, SAN2219 for epilepsy, and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, where a market authorization application is currently under review, and Argentina. In addition, Saniona has two clinical-stage programs available for partnering: Tesomet™, ready to advance to Phase 2b trials in rare eating disorders, and SAN903, ready to enter Phase 1 trials in inflammatory bowel disease. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.
Attachments
Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs
Ämnen i artikeln
Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs
17 december, 2025
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces several new leadership appointments across clinical development, translational medicine, toxicology, and CMC. These additions reinforce the company’s operational platform and position Saniona to efficiently advance its differentiated CNS pipeline toward upcoming clinical and regulatory value inflection points.
“Saniona now has the leadership infrastructure to unlock the significant value potential of our CNS pipeline. These appointments reflect our commitment to disciplined execution and to delivering meaningful clinical results that can create long-term shareholder value,” said Thomas Feldthus, Saniona’s Chief Executive Officer.
The appointments expand Saniona’s core capabilities to progress its CNS assets, including SAN2219 for refractory focal onset seizures, SAN2465 for major depressive disorder, and SAN2668, recently selected as a first-inclass clinical candidate for pediatric epilepsy. All three programs are funded through Phase 1 readouts and are supported by newly filed compound patents providing protection into the 2040s, and each program has first-in-class potential in its respective indication. Phase 2 studies are planned to start in 2028. The expanded leadership team is expected to accelerate development timelines, enhance operational efficiency, and support forthcoming regulatory interactions.
Leadership Commentary
“These appointments significantly enhance our ability to design and execute clinical studies with a rigorous, data-driven approach, increasing the probability of success across our CNS programs,” said Pierandrea Muglia, Chief Medical Officer.
“With expanded capabilities in toxicology and CMC, we can advance our programs efficiently and maintain a proactive regulatory strategy as we enter our next phase of growth,” said Janus Larsen, Chief Operating Officer.
Strategic Leadership Appointments
- Stina Westergaard Frederiksen – Head of Clinical Operations
Over 20 years of clinical development experience across biotech and large pharma, leading programs from design through late-stage execution and building high-performing operational teams. - Martin Damm Olling – Head of Clinical Development
Brings 24 years of R&D expertise from small and large pharma, including two decades in CNS drug development, with successful FDA and EMA approvals and deep experience in clinical strategy and regulatory pathways. - Isabella Premoli – Director of Translational Medicine
Neuroscientist with broad biomarker experience (EEG, TMS, electrophysiology, imaging) and leadership of translational strategies in early-phase research from both biotech and academia. - Alex Rodriguez – Head of Toxicology
More than 20 years of nonclinical and regulatory toxicology experience at large pharma and small pharma companies, including IND and CTA submissions and early-stage development of CNS and small-molecule programs. - Søren Ebdrup – Head of CMC
25 years of small-molecule development experience at mid- and large pharma, overseeing CMC activities across preclinical and clinical phases.
For more information, please contact
Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com
About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for paediatric epilepsy syndromes, SAN2219 for epilepsy, and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, where a market authorization application is currently under review, and Argentina. In addition, Saniona has two clinical-stage programs available for partnering: Tesomet™, ready to advance to Phase 2b trials in rare eating disorders, and SAN903, ready to enter Phase 1 trials in inflammatory bowel disease. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, AstronauTx, and Cephagenix. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.
Attachments
Saniona Bolsters Leadership Team to Accelerate Development of Key CNS Programs
Ämnen i artikeln
Aktierekommendationer
Bostadsmarknaden
Intellego-härvan
Fed
Analyser
Aktierekommendationer
Bostadsmarknaden
Intellego-härvan
Fed
Analyser
Marknadsöversikt
1 DAG %
Senast
1 mån
